Eloxatin

As part of the settlements, the six drug makers will stop selling unauthorized versions of Eloxatin, whose generic name is oxaliplatin, in the U.S. between June 30, 2010 and Aug. 9, 2012, after which the companies can sell their products under license.

Corporate Watch 2010

If the company reaches an agreement with Sun in addition to the six other generic manufacturers, J.P. Morgan analysts said they expect a modest increase in Eloxatin sales in 2011 and 2012 that would raise their estimates of Sanofi's embedded value by 1%.

Sanofi Settles More Eloxatin Patent Suits Mimosa Spencer 2010

Copycat versions of Eloxatin were launched in the U.S. last August after a court ruled in June that generic drug makers who had challenged the Eloxatin patent didn't infringe Sanofi's patents.

Corporate Watch 2010

Sanofi-Aventis said Tuesday it has settled more patent infringement suits with generic drug makers over its cancer drug Eloxatin.

Sanofi Settles More Eloxatin Patent Suits Mimosa Spencer 2010

As part of the settlements, the six drug makers will stop selling unauthorized versions of Eloxatin, whose generic name is oxaliplatin, in the U.S. between June 30, 2010 and Aug. 9, 2012, after which the companies can sell their products under license.

Sanofi Settles More Eloxatin Patent Suits Mimosa Spencer 2010

Copycat versions of Eloxatin were launched in the U.S. last August after a court there ruled in June that generic drug makers who had challenged the Eloxatin patent didn't infringe Sanofi's patents.

Sanofi Settles More Eloxatin Patent Suits Mimosa Spencer 2010

Copycat versions of Eloxatin were launched in the U.S. last August after a court there ruled in June that generic drug makers who had challenged the Eloxatin patent didn't infringe Sanofi's patents.

Sanofi Settles More Eloxatin Patent Suits Mimosa Spencer 2010

As part of the settlements, the six drug makers will stop selling unauthorized versions of Eloxatin, whose generic name is oxaliplatin, in the U.S. between June 30, 2010 and Aug. 9, 2012, after which the companies can sell their products under license.

Sanofi Settles More Eloxatin Patent Suits Mimosa Spencer 2010

Sanofi-Aventis said Tuesday it has settled more patent infringement suits with generic drug makers over its cancer drug Eloxatin.

Sanofi Settles More Eloxatin Patent Suits Mimosa Spencer 2010

If the company reaches an agreement with Sun in addition to the six other generic manufacturers, J.P. Morgan analysts said they expect a modest increase in Eloxatin sales in 2011 and 2012 that would raise their estimates of Sanofi's embedded value by 1%.

Sanofi Settles More Eloxatin Patent Suits Mimosa Spencer 2010